| Zugriffe | |
|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 381 |
| Oktober 2025 | November 2025 | Dezember 2025 | Januar 2026 | Februar 2026 | März 2026 | April 2026 | |
|---|---|---|---|---|---|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 21 | 8 | 2 | 23 | 9 | 30 | 16 |
| Zugriffe | |
|---|---|
| 2021_Frost_etal.pdf | 266 |
